Thrombosis, Venous Clinical Trial
Official title:
ARIXTRA® Physician Adherence to the Prescribing Information in Isolated Superficial Vein Thrombosis (SVT) Patients.
Fondaparinux is an anticoagulant used in the prevention and treatment of thromboembolic
disease. It has recently been approved in the European Union (EU) for the treatment of
patients with isolated superficial vein thrombosis (SVT), i.e. without concomitant deep vein
thrombosis (DVT), of the lower limbs. As part of EU approval, GlaxoSmithKline (GSK)
committed to evaluate physicians' adherence to fondaparinux prescribing information
regarding proper diagnosis and dosing for the treatment of SVT.
The primary objective is to evaluate physicians' adherence to fondaparinux prescribing
information for the treatment of patients with SVT without concomitant DVT.
The study is designed as a non-interventional, retrospective chart review of patients
prescribed fondaparinux to treat their SVT. The study will be conducted in several EU
countries.
ARIXTRA® is a registered trademark of the GlaxoSmithKline group of companies.
n/a
Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04503135 -
Catheter Associated Asymptomatic Thrombosis in Intensive Care Unit
|
||
| Not yet recruiting |
NCT06149533 -
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
|
Phase 3 | |
| Active, not recruiting |
NCT05396157 -
Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
|
||
| Completed |
NCT00312013 -
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT06288906 -
Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems
|
||
| Completed |
NCT00443053 -
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
|
Phase 3 | |
| Completed |
NCT00911157 -
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
|
Phase 3 | |
| Completed |
NCT00320398 -
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
|
Phase 3 | |
| Completed |
NCT01064362 -
Hemorrhage Risk Prescribed Arixtra
|
N/A | |
| Completed |
NCT01444612 -
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
|
N/A | |
| Recruiting |
NCT05710705 -
Bioimpedance Measurement of Abdominal Free Flaps During Arterial and Venous Weaning in Breast Reconstruction
|
N/A | |
| Completed |
NCT00843492 -
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
|
Phase 3 | |
| Not yet recruiting |
NCT06349291 -
Venous Thrombosis After Removal of Central Venous Catheter
|
||
| Recruiting |
NCT06094387 -
The Use of Thrombin Generation Assay in Detection of Central Line Related Thrombosis (CRT) in Critically Ill Patients
|